cancers-logo

Journal Browser

Journal Browser

Cancer Pain: Advances in Pathophysiology and Management

A special issue of Cancers (ISSN 2072-6694).

Deadline for manuscript submissions: 30 July 2026 | Viewed by 903

Special Issue Editors


E-Mail Website
Guest Editor
Department of Medical and Surgical Sciences and Translational Medicine, Sapienza University of Roma, 00189 Rome, Italy
Interests: pain medicine; pain assessment; pain management

Special Issue Information

Dear Colleagues,

Cancer pain remains one of the most frequent and debilitating consequences of malignancy and is typically characterized by a multifaceted pathophysiology involving concurrent nociceptive, neuropathic, and often nociplastic mechanisms, constituting a paradigmatic form of mixed pain. Its biological underpinnings arise from tumor-induced tissue destruction, the release of pro-inflammatory mediators, nerve infiltration or compression, and treatment-related neurotoxicity. Emerging evidence further underscores the pivotal role of tumor–neuron–immune interactions, including cytokine-mediated sensitization and bidirectional neuro-immune signaling, in driving both peripheral and central sensitization. Optimal management, therefore, necessitates a mechanism-oriented, multidisciplinary strategy that integrates pharmacological and non-pharmacological interventions. Opioids and NSAIDs remain the foundation for moderate-to-severe cancer pain, complemented by the rational use of adjuvants such as gabapentinoids, antidepressants, corticosteroids, bisphosphonates, and other anti-resorptive agents. For refractory or anatomically complex presentations, interventional procedures, including targeted nerve blocks, neuromodulation techniques, and vertebral augmentation, offer additional therapeutic value. Early, systematic assessment and individualized multimodal care plans are essential to enhance analgesic efficacy, reduce treatment-related harms, and preserve quality of life. This Special Issue will highlight emerging insights and innovative approaches that may ultimately improve the management of cancer-related pain.

Prof. Dr. Giustino Varrassi
Dr. Matteo Luigi Giuseppe Leoni
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cancer pain
  • mixed pain
  • pathophysiology
  • sensitization
  • multimodal analgesia
  • interventional management

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

30 pages, 2436 KB  
Review
Advances in the Pathophysiology and Management of Cancer Pain: A Scoping Review
by Giustino Varrassi, Antonella Paladini, Y Van Tran, Van Phong Pham, Ameen A. Al Alwany, Giacomo Farì, Annalisa Caruso, Marco Mercieri, Joseph V. Pergolizzi, Alan D. Kaye, Frank Breve, Alberto Corriero, Christopher Gharibo and Matteo Luigi Giuseppe Leoni
Cancers 2026, 18(2), 259; https://doi.org/10.3390/cancers18020259 - 14 Jan 2026
Viewed by 291
Abstract
Background/Objectives: Cancer pain affects 55–95% of patients with advanced malignancy, representing a complex syndrome involving nociceptive, neuropathic and nociplastic mechanisms. Despite therapeutic advances, two-thirds of patients with metastatic cancer experience inadequate pain control. This scoping review synthesizes recent advances in cancer pain pathophysiology [...] Read more.
Background/Objectives: Cancer pain affects 55–95% of patients with advanced malignancy, representing a complex syndrome involving nociceptive, neuropathic and nociplastic mechanisms. Despite therapeutic advances, two-thirds of patients with metastatic cancer experience inadequate pain control. This scoping review synthesizes recent advances in cancer pain pathophysiology and management, focusing on molecular and cellular mechanisms, emerging pharmacological, interventional and technological therapies and key evidence gaps to inform future precision-based pain management strategies. Methods: Following PRISMA-ScR methodology, we searched PubMed, Embase, Scopus, and Web of Science for studies published between January 2022 and September 2025. After screening 3412 records, 278 studies were included and analyzed across different domains: biological mechanisms, pharmacological management, interventional and neuromodulatory approaches, radiotherapy developments, and digital health innovations. Results: Recent mechanistic research reveals cancer pain arises from tumor–neuron–immune crosstalk, with malignant cells secreting neurotrophic factors that promote axonal sprouting and nociceptor sensitization. Genetic polymorphisms and epigenetic modifications contribute to inter-individual pain variability. Management strategies are evolving toward multimodal precision medicine: NSAIDs and opioids remain foundational, complemented by adjuvant agents and interventional procedures including nerve blocks, intrathecal delivery, and neuromodulation (spinal cord and dorsal root ganglion stimulation). Stereotactic body radiotherapy demonstrates superior analgesic durability versus conventional approaches. Digital health innovations, such as mobile applications, remote monitoring, wearables, and AI-enabled predictive models, enable continuous assessment and personalized treatment optimization. Conclusions: Cancer pain management is transitioning toward mechanism-based precision medicine integrating biological insights, advanced interventional techniques, and digital technologies. However, implementation challenges persist, including limited randomized trials for interventional approaches, the incomplete external validation of AI tools, and digital health equity concerns. Future research must prioritize prospective controlled studies and equitable integration into routine care. Full article
(This article belongs to the Special Issue Cancer Pain: Advances in Pathophysiology and Management)
Show Figures

Figure 1

Back to TopTop